Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

The market frenzy that succeeded the interest rate hike has not lasted long, as the U.S. stocks are deep in the red at noon today. The Dow is down by triple digits as fresh economic data and slumping oil prices weigh on the stock markets. There are, however, several stocks that managed to hold on to gains and even trend higher. Let’s have a look at the reasons behind the advance of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), Navistar International Corp (NYSE:NAV), Voltari Corp (NASDAQ:VLTC) and SunCoke Energy Partners LP (NYSE:SXCP).

But why do we track hedge fund activity? From one point of view we can argue that hedge funds are consistently underperforming when it comes to net returns over the last three years, when compared to the S&P 500. But that doesn’t mean that we should completely neglect their activity. There are various reasons behind the low hedge fund returns. Our research indicated that hedge funds’ long positions actually beat the market. In our back-tests covering the 1999-2012 period hedge funds’ top small-cap stocks edged the S&P 500 index by double digits annually. The 15 most popular small-cap stock picks among hedge funds also bested passive index funds by around 60 percentage points over the 36 month period beginning from September 2012 (read the details here).

The U.S. Food and Drug Administration has cleared Actinium Pharmaceuticals Inc (NYSEMKT:ATNM)‘s Iomab-B drug for Phase III trials, according to a press release from the company. Actinium developed Iomab-B to complement the treatment of Acute Myeloid Leukemia, especially in the case of elderly patients who are not eligible for hematopoietic stem cell transplant. The drug is supposed to help patients prepare for such an operation. Shares of Actinium have opened higher this morning and are currently up by 16% from yesterday’s closing price.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

The fund we track have an insignificant presence among shareholders of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM) as only 1% of the common stock was held by five funds at the end of the third quarter. Israel Englander slightly increased his investment in the stock, with Millennium Management reporting ownership of 165,025 shares valued at $292,000 in its latest 13F filing.

Navistar International Corp (NYSE:NAV) is surging today after a better-than-expected earnings report. The company released its fiscal fourth quarter financial results before market open today, posting a loss of $50 million or $0.36 per share when adjusted for one-time gains and costs. Revenues came in at $2.49 billion, down by 17% year over year. Analysts, in turn, were looking for $2.47 billion in revenues and earnings of $0.58 per share. The management has been busy slashing costs, having reported an 18% drop for the quarter, and is confident in its ability to further reduce them. In the conference call, CFO Walter Borst said the company plans cost cuts of approximately $200 million for 2016.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.

More than 51% of Navistar International Corp (NYSE:NAV) was held by 25 hedge funds that we track at the end of September, up from 16 at the end of June. Billionaire Carl Icahn is Navistar’s largest shareholder, which means he also holds the largest position among the funds we follow. In its latest quarterly report, Icahn Capital reported holding 16.3 million shares worth $206 million.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.

Subscribe me to Insider Monkey's Free Daily Newsletter

This is a FREE report from Insider Monkey. Credit Card is NOT required.

We may use your email to send marketing emails about our services. Click here to read our privacy policy.